Status:
COMPLETED
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
Assisi Foundation
Conditions:
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE1
Brief Summary
The prognosis of pediatric patients with hematologic malignancies whose disease is primarily refractory or those who experience a chemotherapy resistant bone marrow relapse is extremely poor. When new...
Detailed Description
This study will evaluate the persistence, phenotype and function of donor NK cells as well as exploring the efficacy of the infusion in research participants with chemotherapy refractory hematologic m...
Eligibility Criteria
Inclusion
- At least two weeks since receipt of last biological therapy, chemotherapy, or radiation therapy.
- Has a suitable adult family member donor available for NK cell donation.
- No current pleural or pericardial effusion.
- HIV negative
- Adequate clinical standing as evidenced by being within multiple renal, hepatic, pulmonary, and neurological required testing parameters.
Exclusion
- Pregnant or lactating
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00697671
Start Date
March 1 2007
End Date
May 1 2013
Last Update
July 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105